Skip to main content

Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.

Journal articles  - Journal Article
Rushton, M; Johnson, C; Dent, S
Published in: Current oncology (Toronto, Ont.)
June 2017

Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important consideration for clinicians and patients. We reviewed the current literature on predicting trastuzumab-related cardiotoxicity and tested a clinical risk score (crs) in a real-world breast cancer population to assess its utility in predicting permanent cardiotoxicity.In this retrospective exploratory cohort study of breast cancer patients referred to a cardio-oncology clinic at a tertiary care centre between October 2008 and August 2014, a crs was calculated for each patient, and a sensitivity analysis was performed.Of the 143 patients included in the study, 62 (43%) experienced a cardiac event, and of those 62 patients, 43 (69%) experienced full recovery of cardiac function. In applying the crs, 119 patients (83%) would be considered at low risk, 14 (10%) at moderate risk, and 10 (7%) at high risk to develop heart failure or cardiomyopathy. When applied to the study population, the high-risk cut-off score had a sensitivity of 0.13 [95% confidence interval (ci): 0.08 to 0.20] and a specificity of 0.94 (95% ci: 0.87 to 0.97). The positive predictive value was 0.07 (95% ci: 0.03 to 0.13), and the negative predictive value was 0.93 (95% ci: 0.87 to 0.96).The crs demonstrated good specificity and negative predictive value for the development of permanent cardiotoxicity in a real-world population of breast cancer patients, suggesting that intensive cardiac monitoring might not be warranted in low-risk patients, but that high-risk patients might benefit from early referral to cardio-oncology for optimization. Further study using the crs in a larger breast cancer population is warranted to identify patients at low risk of long-term trastuzumab-related cardiotoxicity.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Current oncology (Toronto, Ont.)

DOI

EISSN

1718-7729

ISSN

1198-0052

Publication Date

June 2017

Volume

24

Issue

3

Start / End Page

176 / 180

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rushton, M., Johnson, C., & Dent, S. (2017). Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Current Oncology (Toronto, Ont.), 24(3), 176–180. https://doi.org/10.3747/co.24.3349
Rushton, M., C. Johnson, and S. Dent. “Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.” Current Oncology (Toronto, Ont.) 24, no. 3 (June 2017): 176–80. https://doi.org/10.3747/co.24.3349.
Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Current oncology (Toronto, Ont). 2017 Jun;24(3):176–80.
Rushton, M., et al. “Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.” Current Oncology (Toronto, Ont.), vol. 24, no. 3, June 2017, pp. 176–80. Epmc, doi:10.3747/co.24.3349.
Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Current oncology (Toronto, Ont). 2017 Jun;24(3):176–180.

Published In

Current oncology (Toronto, Ont.)

DOI

EISSN

1718-7729

ISSN

1198-0052

Publication Date

June 2017

Volume

24

Issue

3

Start / End Page

176 / 180

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis